On Demand 2024 Friday PM General Sessions

This course includes the following sessions:

  • Thanks to the Larynx
  • Atopy in Pregnancy: Implications for Mom and Baby
  • WAO World Allergy Forum: The Skin as an Immunological Target
  • Personalized Pediatric Food Allergy Management: Confronting the (Green) Monster Under the Bed

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Identify various presentations of laryngeal hypersensitivity and VCD/ILO frequently encountered in allergy/immunology practice.
  • Formulate a differential, diagnostic approach, and treatment plan for adult patients presenting with cough.
  • Describe different treatment techniques of laryngeal hypersensitivity, VCD/ILO, cough suppression techniques, breathing exercises, and counseling treatment of patients with these conditions.
  • Identify evidence-based approaches to asthma control in pregnant women.
  • Develop counseling strategies for breastfeeding mothers on indications for allergen avoidance and food introduction.
  • Describe approaches to beta lactam allergy in pregnant populations stratified by risk. Identify management strategies for urticaria, eczema, and other skin diseases in pregnant women.
  • Define the term immunonutrition and its role in tolerance development.
  • Provide guidance on how to determine if strict avoidance is required: individualizing the approach.
  • Give practical instructions regarding post OIT dosing using retail foods.
  • Describe current concepts in the diagnosis, comorbidities, treatment, and prognosis of patients with atopic dermatitis.
  • Discuss the main types of hereditary angioedema, keys to diagnosis, and advances in current treatment.
  • Explain the mechanisms and differences between acute and chronic urticaria, spontaneous and autoimmune urticaria, as well as the most recent advances in biomarkers and treatment.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
  • 6.00 CBRN
Course opens: 
11/11/2024
Course expires: 
11/10/2027
Part of: 
On Demand ACAAI 2024 Annual Scientific Meeting General Sessions
Rating: 
0

Gerald B. Lee, MD, FACAAI
Lindsey E. Moore, DO, FACAAI
Andrej A. Petrov, MD, FACAAI
Richard Irwin, MD
Reynold A. Panettieri, Jr., MD
William C. Anderson, III, MD, FACAAI
Lyda Cuervo-Pardo, MD, FACAAI
Suzanne Y. Ngo, MD
Ruchi Shah, MD, FACAAI
Kirsi M. Jarvinen-Seppo, MD, PhD
Irene J. Mikhail, MD, FACAAI
Gailen D. Marshall, Jr, MD, PhD, FACAAI
Bryan L. Martin, DO, FACAAI
Luz S. Fonacier, MD, FACAAI
Timothy J. Craig, DO, FACAAI
María I. Rojo-Guiterrez, MD
Dana V. Wallace, MD, FACAAI
Katherine L. McCormack, MD
Charlene M. Dunaway-Altamirano, MD, PhD
Carina Venter, PhD, RD
Anna H. Nowak-Wegrzyn, MD, PhD, FACAAI
Marion E. Groetch, RDN

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Attendance
  • 6.00 CBRN
Please login or create an account to take this course.